Adoptive T-cell Therapies Segment of The Immuno-oncology Market to Reach Revenues of $3.9 Billion by 2022
March 19, 2018
March 19, 2018
SANTA CLARA, California, March 19 -- Frost and Sullivan, a provider of market research and analysis, growth strategy consulting and corporate training services across multiple industries, issued the following news release:
Frost & Sullivan's latest analysis, Immuno-oncology Therapeutics Market--Adoptive T-cell Therapies, Forecast to 2022, finds that the market is expected to generate revenues of $3.9 billion by 2022. Promising clinical trials in artificial T cell receptors (CAR- . . .
Frost & Sullivan's latest analysis, Immuno-oncology Therapeutics Market--Adoptive T-cell Therapies, Forecast to 2022, finds that the market is expected to generate revenues of $3.9 billion by 2022. Promising clinical trials in artificial T cell receptors (CAR- . . .